Dysport® (abobotulinumtoxinA) – Expanded indication
September 26, 2019 - Ipsen Biopharmaceuticals announced the FDA approval of Dysport (abobotulinumtoxinA), for the treatment of upper limb spasticity in pediatric patients 2 years of age and older, excluding spasticity caused by cerebral palsy.
Download PDF
